US Patent 8,268,804: Scope, Claim Construction, Expiration, Orange Book Status, and Minocycline Patent Landscape

US Patent 8,268,804 protects a weight-based, once-daily oral minocycline regimen for acne using a controlled-release dosage form. The patent does not broadly cover every extended-release minocycline product. Its independent claim requires the combined use of: body-weight determination, dose selection, no loading dose, a daily exposure of 0.7 to 1.3 mg/kg, specified dissolution performance in gastric fluid, and treatment of acne.

The most commercially relevant embodiments correspond to 45 mg, 90 mg, and 135 mg once-daily minocycline extended-release products, including the Solodyn product line. The patent’s value depends on whether a competing product meets every limitation of claim 1 or an asserted dependent claim, particularly the pharmacokinetic dosing range and dissolution profile.

What does US Patent 8,268,804 cover?

US 8,268,804 covers a method of treating acne with a controlled-release oral minocycline dosage form selected according to the patient’s body weight.

The independent claim requires all of the following:

Claim limitation	Required condition
Disease	Treatment of acne
Route and form	Oral dosage form
Patient assessment	Determining the person’s body weight
Dose selection	Selecting the dosage form based on body weight
Loading regimen	No initial loading dose
Daily exposure	0.7 to 1.3 mg/kg/day minocycline
Administration	Once daily
Active ingredient	Minocycline or a pharmaceutically acceptable salt
Release system	Controlled-release carrier
Dissolution profile	One of two specified gastric-fluid release profiles

The two claimed dissolution alternatives are:

25% to 52% released within one hour, 53% to 89% within two hours, and at least 90% within four hours; or
30% to 52% released within one hour, 53% to 84% within two hours, and at least 85% within four hours.

The claim therefore combines a clinical dosing protocol with a product-performance limitation. A product that uses the same nominal strength but has a materially different dissolution profile may avoid literal infringement of claim 1, subject to claim construction and potential doctrine-of-equivalents issues.

What are the key technical limitations in claim 1?

Weight-based dose selection

The claim requires the prescriber or treatment method to determine body weight and select the dosage form accordingly. A fixed-dose prescription that is not selected by reference to body weight presents a potential noninfringement position.

The required range is broad enough to capture an approximately 1 mg/kg/day regimen. For example:

A 45 mg dose corresponds to approximately 1 mg/kg/day for a 45 kg patient.
A 90 mg dose corresponds to approximately 1 mg/kg/day for a 90 kg patient.
A 135 mg dose corresponds to approximately 1 mg/kg/day for a 135 kg patient.

Claim 5 narrows the range to “about 1 mg/kg/day,” and claim 6 limits the dosage strengths to 45 mg, 90 mg, and 135 mg.

No initial loading dose

The absence of an initial loading dose is an express limitation. A treatment protocol requiring a loading dose would not literally satisfy this element. Conversely, a product label that permits or recommends a loading dose does not automatically avoid infringement if the accused method is practiced without the loading dose.

Once-daily administration

The claim is directed to once-daily administration. Twice-daily immediate-release minocycline products fall outside the literal scope of this limitation. A once-daily extended-release product remains within the relevant risk area if it also meets the weight-based dosing and dissolution requirements.

Controlled-release carrier

The dosage form must contain a carrier that controls minocycline release. Claim 2 identifies hydroxypropylmethylcellulose, hydroxypropylcellulose, and polyvinylpyrrolidone as possible carrier ingredients. These limitations provide narrower claim positions but also create formulation-specific design-around opportunities.

Gastric-fluid dissolution profile

The dissolution limitation is central to the patent. The claimed release windows define the permitted amount released at one, two, and four hours. Testing conditions matter, including:

The identity and pH of the gastric-fluid medium.
Agitation speed.
Apparatus type.
Temperature.
Sampling times.
Assay method.
Whether the percentages are calculated against labeled minocycline content or total dosage-form content.

A competing manufacturer would normally compare its development and regulatory dissolution data against these parameters. Minor changes in formulation may move a product outside one or more claimed windows, but the validity and infringement analysis would depend on the construction of the numerical ranges and the testing methodology.

How do claims 2 through 14 narrow the patent?

Claims 2 through 14 create a formulation and strength-specific claim ladder.

Claim	Added limitation
2	Carrier includes HPMC, HPC, or PVP
3	Carrier is 20% to 30% by total dosage-form weight
4	Salt is minocycline hydrochloride
5	Dose is about 1 mg/kg/day
6	Strength is 45 mg, 90 mg, or 135 mg
7	Slow-dissolving carrier is included
8	Slow-dissolving carrier is included
9	For 45 mg or 90 mg, slow-dissolving carrier is 26% to 28%
10	For 135 mg, slow-dissolving carrier is 22% to less than 25%
11	Fast-dissolving carrier is also included
12	Fast-dissolving carrier has intra- and extragranular components
13	Intragranular fast carrier and slow carrier each exceed extragranular fast carrier
14	Film coat is 2% to 3% of total coated dosage-form weight

Claims 9, 10, and 13 are particularly formulation-specific. They may be useful against products closely following the patented manufacturing architecture, but they are easier to design around than claim 1 because a competitor can alter carrier percentages, granulation structure, or coating weight.

What formulations are protected by US 8,268,804?

The patent reaches controlled-release minocycline tablets or capsules that use a combination of fast- and slow-dissolving excipient systems and produce the claimed gastric-fluid release profile.

The most important protected formulation concepts are:

Minocycline hydrochloride as the active ingredient.
Hydrophilic polymer carriers such as HPMC or HPC.
PVP as a possible carrier or processing aid.
A slow-dissolving carrier.
An optional fast-dissolving carrier.
Separate intragranular and extragranular fast-dissolving components.
Strength-specific carrier loading.
A relatively narrow film-coat weight.

The claims do not require every listed excipient. Claims 2, 7, 8, and 11 introduce those ingredients progressively. A product may infringe claim 1 without infringing claims 2 through 14 if it satisfies the independent claim through a different controlled-release system.

What is the patent’s legal scope?

Literal infringement

Literal infringement requires the accused method to meet every limitation of an asserted claim. For claim 1, the following questions are decisive:

Was the patient’s body weight determined?
Was the dosage form selected based on that weight?
Was the drug administered once daily?
Was there no initial loading dose?
Was the delivered dose between 0.7 and 1.3 mg/kg/day?
Did the dosage form contain minocycline or a salt?
Did the carrier produce one of the claimed dissolution profiles?

A product comparison based only on labeled strength is incomplete. The patent claims a method of treatment, not merely a tablet composition.

Indirect infringement

A generic label or prescribing instructions may create inducement risk if they direct physicians to practice the claimed weight-based, no-loading-dose, once-daily method. The analysis would turn on the exact labeling language, available dosing strengths, treatment instructions, and whether the label encourages conduct satisfying all limitations.

A generic company may seek a section viii carve-out for patented methods of use. That strategy is less straightforward where the claimed method is embedded in the dosing instructions for the entire product rather than limited to a separate indication.

Doctrine of equivalents

A formulation that falls just outside a numerical release range may still present litigation risk if the patentee alleges an equivalent release function. The defense would focus on prosecution-history estoppel, the criticality of the numerical boundaries, and whether the accused release profile performs substantially the same function in substantially the same way.

When does US Patent 8,268,804 lose exclusivity?

The patent is generally reported with a June 29, 2027 expiration date, subject to the applicable patent-term adjustment and any regulatory extension reflected in official records. The relevant Orange Book entry should control the marketed-product patent listing and expiration information for FDA purposes.[2]

The patent’s commercial exclusivity should be separated from other forms of exclusivity:

Exclusivity category	Relevance
Patent exclusivity	Depends on the expiration and enforceability of listed patents
New-drug exclusivity	Solodyn’s original FDA exclusivity period has expired
Pediatric exclusivity	Any six-month pediatric extension would be reflected in FDA records
Orphan exclusivity	Not applicable to acne treatment
Generic exclusivity	Depends on the first substantially complete ANDA with a qualifying Paragraph IV certification

The patent’s expiration does not eliminate other listed patents. A generic entrant must evaluate the full Orange Book estate, including formulation, method-of-use, and other listed patents.

What is the Orange Book status of the minocycline extended-release products?

The relevant branded product is Solodyn, an extended-release minocycline hydrochloride product approved for the treatment of moderate to severe acne vulgaris in patients 12 years of age and older. FDA labeling identifies 45 mg, 90 mg, and 135 mg extended-release tablets, with once-daily administration and dosing based on body weight.[1]

The FDA Orange Book is the controlling source for:

Current reference-listed drug status.
Listed patents.
Patent-use codes.
Expiration dates.
Therapeutic-equivalence ratings for approved generic products.[2]

Because Orange Book listings and patent records can change, a transaction or launch decision should use the current FDA listing rather than historical litigation summaries. US 8,268,804 is relevant because its claims track the product’s weight-based, once-daily extended-release dosing architecture.

Which companies challenged the Solodyn patent estate?

Solodyn faced generic competition from multiple ANDA filers, including major generic manufacturers that pursued approval for minocycline extended-release products. Public litigation and settlement records associated with the Solodyn franchise include disputes involving Actavis and other generic applicants, with assertions directed at patents covering extended-release minocycline formulations and treatment methods.[3]

The practical issues in those disputes included:

Paragraph IV invalidity and noninfringement positions.
Whether the proposed generic formulation matched the patented dissolution profile.
Whether the generic label induced the claimed acne-treatment method.
The scope of the listed patent claims.
Launch timing under settlement agreements.
The effect of patent expiration on authorized or licensed generic entry.

A Paragraph IV notice is not itself evidence that the patent is invalid. It is an ANDA applicant’s statutory certification that the listed patent is invalid, unenforceable, or will not be infringed. Filing an infringement action within the statutory period can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions.[4]

What patent litigation affects US 8,268,804?

The patent’s litigation risk is linked to ANDA filings for minocycline hydrochloride extended-release products. A complete litigation review should distinguish:

Cases asserting US 8,268,804 specifically.
Cases asserting related Solodyn patents.
Cases involving the same generic product but different listed patents.
Cases dismissed after settlement.
Cases resolved by consent judgment.
Cases in which a generic received a license or agreed to delayed entry.

The principal litigation questions are claim construction, dissolution testing, formulation equivalence, and inducement based on the proposed label. The most vulnerable portion of the patent is the method-of-treatment framing, because a generic applicant may argue that its label does not require body-weight-based selection or the claimed no-loading-dose regimen. The strongest infringement case arises when the generic label expressly reproduces the branded dosing table and the generic’s release data falls within the claimed ranges.

How strong is the patent estate for Solodyn?

US 8,268,804 has a moderate-to-strong claim position against close copies of the branded product, but a narrower position against redesigned extended-release products.

Strengths

Claim 1 combines clinical-use and formulation limitations.
The 45 mg, 90 mg, and 135 mg strengths map directly to commercially relevant products.
The once-daily, weight-based regimen is reflected in the FDA-approved product labeling.
The controlled-release profile provides an objective product-comparison metric.
Dependent claims cover specific polymer systems and carrier proportions.

Vulnerabilities

Claim 1 requires proof of a treatment method, not merely sale of a dosage form.
A competitor may alter its label to avoid explicit weight-based selection.
Dissolution testing may place a product outside the claimed windows.
Carrier percentages and granulation architecture are relatively easy to modify.
The patent expires before the end of the decade, limiting long-term lifecycle value.
The claims do not broadly cover all minocycline extended-release products.

The estate is stronger against a product designed to replicate Solodyn’s label and release characteristics than against a product using a different extended-release technology or a substantially different dosing protocol.

What generic launch scenarios exist?

Launch after patent expiration

This is the lowest litigation-risk scenario if no other Orange Book patent blocks approval. The generic can launch after expiration of the relevant patents and satisfaction of FDA approval requirements.

Licensed early entry

A settlement may permit entry before the nominal patent expiration date. The entry date may differ by manufacturer and can depend on commercial terms, authorized-generic arrangements, or other restrictions.

Paragraph IV launch

A first filer may launch at risk after the relevant regulatory stay expires or after prevailing in litigation. The generic could face damages or injunctive relief if the patent is later upheld and found infringed.

Section viii carve-out

A generic may remove or modify patented method-of-use information from its label. This strategy is more difficult when the patented method is closely tied to the product’s principal approved acne indication and standard dosing instructions.

How does US 8,268,804 compare with competing minocycline products?

Product category	Typical dosing concept	Release technology	Risk under US 8,268,804
Immediate-release minocycline	Often multiple daily doses	No controlled release	Generally low
Branded Solodyn-type product	Once daily, weight-based	Controlled release	High if dissolution matches
Generic minocycline ER	Once daily	Product-specific	Depends on label and release data
Alternative ER formulation	Once daily or modified schedule	Different polymer or matrix	Moderate to low
Topical minocycline	Topical administration	Local delivery	Outside the oral dosage-form limitation
Sarecycline	Different tetracycline derivative	Oral immediate or conventional release	Not a minocycline product; outside the active-ingredient limitation

Sarecycline and topical minocycline products compete in acne treatment but do not ordinarily implicate this patent because the claim requires oral minocycline or a pharmaceutically acceptable salt.

What manufacturing and geographic barriers remain?

The patent is a United States right. It does not directly block manufacture, sale, or use in Canada, Europe, Japan, or other jurisdictions. Separate national patents and regulatory exclusivities must be reviewed for each market.

The principal US manufacturing barrier is reproducible control of the dissolution profile. A manufacturer must maintain:

Polymer grade and viscosity.
Granulation conditions.
Intragranular and extragranular excipient ratios.
Tablet compression parameters.
Coating weight.
Minocycline content uniformity.
Release performance over shelf life.

A formulation that passes development dissolution testing may fail commercial-scale or stability testing if polymer hydration, compression force, or coating thickness changes. These manufacturing controls create practical barriers even where a competitor has designed around the literal claim language.

What is the revenue exposure from this patent?

The patent’s revenue exposure is concentrated in branded extended-release minocycline sales and the timing of generic entry. The commercially important strengths are 45 mg, 90 mg, and 135 mg. Once-daily dosing and the approved acne indication make the product susceptible to direct substitution after generic approval.

Revenue exposure depends on:

The remaining life of US 8,268,804.
Other Orange Book patents.
The number of approved generic applicants.
Any settlement-based entry dates.
Generic substitution and formulary behavior.
Whether the branded company retains an authorized generic strategy.
The commercial importance of the acne franchise to the product owner.

US 8,268,804 is therefore a late-lifecycle protection asset. Its value is highest in litigation, settlement negotiations, and launch-timing analysis, rather than in supporting a long-term new-product exclusivity strategy.

Key Takeaways

US 8,268,804 claims a method, not a generic minocycline composition.
Claim 1 requires acne treatment, oral administration, body-weight determination, weight-based dosage selection, no loading dose, once-daily administration, 0.7 to 1.3 mg/kg/day exposure, and one of two gastric-fluid dissolution profiles.
Claims 5 and 6 specifically target approximately 1 mg/kg/day and the 45 mg, 90 mg, and 135 mg strengths.
Claims 2 through 14 add polymer, carrier-percentage, granulation, slow-release, fast-release, and coating limitations.
The patent is generally associated with the Solodyn extended-release minocycline product and is reported to expire on June 29, 2027.
Generic risk is highest when the ANDA label follows the branded weight-based dosing table and the formulation matches the claimed release profile.
The patent is easier to design around through a different release profile, carrier system, dosing instruction, or treatment protocol.
Paragraph IV litigation and settlement terms must be analyzed across the entire Orange Book estate, not US 8,268,804 in isolation.
Generic entry after patent expiry remains subject to other listed patents, FDA approval, and any applicable regulatory exclusivity.

FAQs About US Patent 8,268,804

Does US 8,268,804 cover all 90 mg minocycline extended-release tablets?

No. The 90 mg strength is relevant under claim 6, but infringement also requires the limitations inherited from claim 1, including the weight-based method, no loading dose, once-daily administration, and claimed dissolution profile.

Can a generic avoid this patent by using the same minocycline dose twice daily?

Potentially. Twice-daily administration would not literally meet the once-daily limitation in claim 1. The generic would still need to assess other Solodyn patents and any infringement theory based on the actual label and product use.

Is a different polymer automatically outside US 8,268,804?

No. Claim 1 does not require HPMC, HPC, or PVP. Those ingredients appear in dependent claim 2. A different polymer may still infringe claim 1 if the product satisfies the independent claim’s controlled-release and dissolution requirements.

Does FDA approval of a generic prove that US 8,268,804 is invalid?

No. FDA approval and patent validity are separate questions. A generic may receive approval after a Paragraph IV certification, a section viii carve-out, patent expiry, settlement, or resolution of the statutory stay.

Does US 8,268,804 protect minocycline for rosacea or other diseases?

The issued independent claim is directed to treatment of acne. Use for another disease would not satisfy the express acne-treatment limitation, although other patents or infringement theories could apply to different products or indications.

References

U.S. Food and Drug Administration. (2023). Solodyn (minocycline hydrochloride) extended-release tablets: Prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,268,804, Methods for treating acne using a dosage form comprising minocycline.
21 U.S.C. § 355(j). (2023). Abbreviated applications for new drugs.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006262428	⤷ Start Trial
Canada	2613273	⤷ Start Trial
China	101208097	⤷ Start Trial
European Patent Office	1898925	⤷ Start Trial
Japan	2008543936	⤷ Start Trial
Japan	2013213047	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,268,804